Modulation of G Protein-coupled Adenosine Receptors by Strategically Functionalized Agonists and Antagonists Immobilized on Gold Nanoparticles

Overview

Journal Purinergic Signal

Publisher Springer

Date 2012 Nov 27

PMID 23179047

Citations 7

Authors

P Suresh Jayasekara

Khai Phan

Dilip K Tosh

T Santhosh Kumar

Steven M Moss

Guofeng Zhang

Joseph J Barchi Jr

Zhan-Guo Gao

Kenneth A Jacobson

Affiliations

Soon will be listed here.

Abstract

Gold nanoparticles (AuNPs) allow the tuning of pharmacokinetic and pharmacodynamic properties by active or passive targeting of drugs for cancer and other diseases. We have functionalized gold nanoparticles by tethering specific ligands, agonists and antagonists, of adenosine receptors (ARs) to the gold surface as models for cell surface interactions with G protein-coupled receptors (GPCRs). The AuNP conjugates with chain-extended AR ligands alone (PEGylated nucleosides and nonnucleosides, anchored to the Au via thioctic acid) were found to be insoluble in water due to hydrophobic entities in the ligand. Therefore, we added a second, biologically inactive pendant moiety to increase the water solubility, consisting of a PEGylated chain terminating in a carboxylic or phosphate group. The purity and stability of the immobilized biologically active ligand were examined by ultrafiltration and HPLC. Pharmacological receptor binding studies on these GPCR ligand-derivatized AuNPs (2-5 nm in diameter), performed using membranes of mammalian cells stably expressing human A1, A2A, and A3ARs, showed that the desired selectivity was retained with K(i) values (nanomolar) of A3AR agonist 21b and A2AAR antagonists 24 and 26a of 14 (A3), 34 (A2A), and 69 (A2A), respectively. The corresponding monomers displayed K i values of 37, 61, and 1,420 nM, respectively. In conclusion, we have synthesized stable, water-soluble AuNP derivatives of tethered A3 and A2AAR ligands that retain the biological properties of their monomeric ligands and are intended for therapeutic and imaging applications. This is the first prototypical application to gold carriers of small molecule (nonpeptide) GPCR ligands, which are under investigation for treatment of cancer and inflammatory diseases.

Citing Articles

RNA therapeutics in targeting G protein-coupled receptors: Recent advances and challenges.

Yuan W, Shi X, Lee L Mol Ther Nucleic Acids. 2024; 35(2):102195.

PMID: 38741614 PMC: 11089380. DOI: 10.1016/j.omtn.2024.102195.

A Chemical Biological Approach to Study G Protein-Coupled Receptors: Labeling the Adenosine A Receptor Using an Electrophilic Covalent Probe.

Beerkens B, Koc C, Liu R, Florea B, Le Devedec S, Heitman L ACS Chem Biol. 2022; 17(11):3131-3139.

PMID: 36279267 PMC: 9679998. DOI: 10.1021/acschembio.2c00589.

Purinergic Signaling and Inflammasome Activation in Psoriasis Pathogenesis.

Ferrari D, Casciano F, Secchiero P, Reali E Int J Mol Sci. 2021; 22(17).

PMID: 34502368 PMC: 8430580. DOI: 10.3390/ijms22179449.

Application of Nanoparticles for Targeting G Protein-Coupled Receptors.

Ma X, Xiong Y, Lee L Int J Mol Sci. 2018; 19(7).

PMID: 29996469 PMC: 6073629. DOI: 10.3390/ijms19072006.

Pharmacokinetics, biodistribution and metabolism of squalenoyl adenosine nanoparticles in mice using dual radio-labeling and radio-HPLC analysis.

Gaudin A, Lepetre-Mouelhi S, Mougin J, Parrod M, Pieters G, Garcia-Argote S J Control Release. 2015; 212:50-8.

PMID: 26087468 PMC: 4534517. DOI: 10.1016/j.jconrel.2015.06.016.

References

Khlebtsov N, Dykman L . Biodistribution and toxicity of engineered gold nanoparticles: a review of in vitro and in vivo studies. Chem Soc Rev. 2010; 40(3):1647-71. DOI: 10.1039/c0cs00018c. View

Han G, Ghosh P, Rotello V . Functionalized gold nanoparticles for drug delivery. Nanomedicine (Lond). 2007; 2(1):113-23. DOI: 10.2217/17435889.2.1.113. View

Henderson L, Altimari J, Dyson G, Servinis L, Niranjan B, Risbridger G . A comparative assessment of α-lipoic acid N-phenylamides as non-steroidal androgen receptor antagonists both on and off gold nanoparticles. Bioorg Chem. 2011; 40(1):1-5. DOI: 10.1016/j.bioorg.2011.11.007. View

Chithrani D . Intracellular uptake, transport, and processing of gold nanostructures. Mol Membr Biol. 2010; 27(7):299-311. DOI: 10.3109/09687688.2010.507787. View

Pirollo K, Chang E . Does a targeting ligand influence nanoparticle tumor localization or uptake?. Trends Biotechnol. 2008; 26(10):552-8. DOI: 10.1016/j.tibtech.2008.06.007. View

Das A, Ko H, Burianek L, Barrett M, Harden T, Jacobson K . Human P2Y(14) receptor agonists: truncation of the hexose moiety of uridine-5'-diphosphoglucose and its replacement with alkyl and aryl groups. J Med Chem. 2009; 53(1):471-80. PMC: 2804908. DOI: 10.1021/jm901432g. View

Huang X, Peng X, Wang Y, Wang Y, Shin D, El-Sayed M . A reexamination of active and passive tumor targeting by using rod-shaped gold nanocrystals and covalently conjugated peptide ligands. ACS Nano. 2010; 4(10):5887-96. PMC: 2964428. DOI: 10.1021/nn102055s. View

Cohen S, Stemmer S, Zozulya G, Ochaion A, Patoka R, Barer F . CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver. J Cell Physiol. 2011; 226(9):2438-47. PMC: 3474360. DOI: 10.1002/jcp.22593. View

Jacobson K, Gao Z . Adenosine receptors as therapeutic targets. Nat Rev Drug Discov. 2006; 5(3):247-64. PMC: 3463109. DOI: 10.1038/nrd1983. View

10.

Kecskes A, Tosh D, Wei Q, Gao Z, Jacobson K . GPCR ligand dendrimer (GLiDe) conjugates: adenosine receptor interactions of a series of multivalent xanthine antagonists. Bioconjug Chem. 2011; 22(6):1115-27. PMC: 3116093. DOI: 10.1021/bc1005812. View

11.

Gessi S, Merighi S, Varani K, Borea P . Adenosine receptors in health and disease. Adv Pharmacol. 2011; 61:41-75. DOI: 10.1016/B978-0-12-385526-8.00002-3. View

12.

Tosh D, Chinn M, Yoo L, Kang D, Luecke H, Gao Z . 2-Dialkynyl derivatives of (N)-methanocarba nucleosides: 'Clickable' A(3) adenosine receptor-selective agonists. Bioorg Med Chem. 2009; 18(2):508-17. PMC: 2818678. DOI: 10.1016/j.bmc.2009.12.018. View

13.

Cai W, Gao T, Hong H, Sun J . Applications of gold nanoparticles in cancer nanotechnology. Nanotechnol Sci Appl. 2013; 1:17-32. PMC: 3808249. DOI: 10.2147/nsa.s3788. View

14.

Yu L, Coelho J, Zhang X, Fu Y, Tillman A, Karaoz U . Uncovering multiple molecular targets for caffeine using a drug target validation strategy combining A 2A receptor knockout mice with microarray profiling. Physiol Genomics. 2009; 37(3):199-210. PMC: 2685498. DOI: 10.1152/physiolgenomics.90353.2008. View

15.

Nordstedt C, Fredholm B . A modification of a protein-binding method for rapid quantification of cAMP in cell-culture supernatants and body fluid. Anal Biochem. 1990; 189(2):231-4. DOI: 10.1016/0003-2697(90)90113-n. View

16.

Lappano R, Maggiolini M . G protein-coupled receptors: novel targets for drug discovery in cancer. Nat Rev Drug Discov. 2011; 10(1):47-60. DOI: 10.1038/nrd3320. View

17.

Boisselier E, Astruc D . Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity. Chem Soc Rev. 2009; 38(6):1759-82. DOI: 10.1039/b806051g. View

18.

Aillon K, Xie Y, El-Gendy N, Berkland C, Forrest M . Effects of nanomaterial physicochemical properties on in vivo toxicity. Adv Drug Deliv Rev. 2009; 61(6):457-66. PMC: 2743376. DOI: 10.1016/j.addr.2009.03.010. View

19.

Verma A, Stellacci F . Effect of surface properties on nanoparticle-cell interactions. Small. 2009; 6(1):12-21. DOI: 10.1002/smll.200901158. View

20.

Kumar T, Mishra S, Deflorian F, Yoo L, Phan K, Kecskes M . Molecular probes for the A2A adenosine receptor based on a pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine scaffold. Bioorg Med Chem Lett. 2010; 21(9):2740-5. PMC: 3081901. DOI: 10.1016/j.bmcl.2010.11.082. View